LSP et al. in €67m series-A for Alizé Pharma 3

Francesca Veronesi
31 July 2019

Tweet
Facebook
LinkedIn
Google plus
Send to

A consortium of investors led by LSP has backed a €67m series-A round for Alizé Pharma 3, a French company developing treatments for rare endocrine and metabolic diseases.

Participating in the financing were new investors Novo Ventures, Kurma Partners, Orbimed, Pontifax, Partners Innovation Fund and BPI France, as well as existing shareholders Sham Innovation Santé, Turenne Capital, Crédit Agricole Création and TAB Consulting.

The fresh capital will help the company advance its current programmes in hypoparathyroidism and severe insulin resistance into clinical development, and to further strengthen its product portfolio in rare endocrine and metabolic diseases. In addition, proceeds will be used to grow Alizé Pharma 3's team based in Lyon, and open a subsidiary in Boston, US.

BPI France invested via Innobio 2. The fund was announced in Q3 2018 and its target was set at €250m. The fund completed its first investment in April this year, backing France-based cancer drug developer NH TherAguix alongside Omnes Capital, Supernova Invest and Arbevel.

Company
Founded in 2015, Alizé Pharma 3 is a developer of therapeutic peptides for rare endocrine and metabolic diseases. Its first two assets are AZP-3601, a PTH analog for hypoparathyroidism; and AZP-3404, a peptide leveraging the biology of IGFBP2 for treating syndromes of severe insulin resistance. The company is based in Lyon.

People
Alizé Pharma 3 – Thierry Abribat (founder, CEO).
LSP – Felice Verduyn-Van Weegen (investment manager).
Novo Ventures – Jørgen Søberg Petersen (venture partner).
Kurma Partners – Thierry Laugel (managing partner).